An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.

ABSTRACT:

Purpose

This study was aimed to analyze the association of very early molecular response to nilotinib with the achievement of deep molecular response (MR4) at 18 months. We hypothesized that the BCR-ABL1 levels during the first 3 months of therapy, and the kinetics of their descent in this period, could be predictive of deep molecular response thereafter.

Methods

This substudy of the ENEST1st trial included 60 patients with chronic myeloid leukemia in chronic phase treated with front-line nilotinib, and BCR-ABL1IS levels were measured using GUS as the control gene. The analysis included seven time points during the first trimester of treatment (baseline and fortnightly thereafter).

Results

The rates of MMR at 12 months, and of MR4 at 18 months (primary variable of the

SUBMITTER: Steegmann JL 

PROVIDER: S-EPMC5653730 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature